Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer

Authors: Genni M Newnham, Matthew Conron, SueAnne McLachlan, Alexander Dobrovic, Hongdo Do, Jason Li, Kenneth Opeskin, Natalie Thompson, Gavin M Wright, David M Thomas

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

The aim of this study was to identify critical genes involved in non-small cell lung cancer (NSCLC) pathogenesis that may lead to a more complete understanding of this disease and identify novel molecular targets for use in the development of more effective therapies.

Methods

Both transcriptional and genomic profiling were performed on 69 resected NSCLC specimens and results correlated with mutational analyses and clinical data to identify genetic alterations associated with groups of interest.

Results

Combined analyses identified specific patterns of genetic alteration associated with adenocarcinoma vs. squamous differentiation; KRAS mutation; TP53 mutation, metastatic potential and disease recurrence and survival. Amplification of 3q was associated with mutations in TP53 in adenocarcinoma. A prognostic signature for disease recurrence, reflecting KRAS pathway activation, was validated in an independent test set.

Conclusions

These results may provide the first steps in identifying new predictive biomarkers and targets for novel therapies, thus improving outcomes for patients with this deadly disease.
Appendix
Available only for authorised users
Literature
1.
Maione P, et al: Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist. 2006, 11: 274-84. 10.1634/theoncologist.11-3-274. 3CrossRefPubMed
2.
Morgan T, et al: Molecular profiling of Giant Cell Tumour of Bone and Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor kB. American Journal of Pathology. 2005, 167: 117-28. 10.1016/S0002-9440(10)62959-8.CrossRefPubMedPubMedCentral
3.
Weiss MM, et al: Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol. 2004, 26: 307-17. 5-6PubMedPubMedCentral
4.
Krypuy M, et al: High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer. 2007, 7: 10.1186/1471-2407-7-168. 168 PMID 17764544
5.
Krypuy M, et al: High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006, 6: 10.1186/1471-2407-6-295. 295 PMID 17184525
6.
Smyth G: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology. 2004, Article 3
7.
Smyth G, et al: The use of with-in array replicate spots for assessing expression in microarray experiments. Bioinformatics. 2005, 2067
8.
Olshen A, et al: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004, 5: 557-72. 10.1093/biostatistics/kxh008.CrossRefPubMed
9.
Petersen I, et al: Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res. 1997, 57: 2331-5. 12PubMed
10.
Bjorkqvist A, et al: DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer. 1998, 22: 79-82. 10.1002/(SICI)1098-2264(199805)22:1<79::AID-GCC11>3.0.CO;2-D. 1CrossRefPubMed
11.
Pei J, et al: Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer. 2001, 31: 282-87. 10.1002/gcc.1145. 3CrossRefPubMed
12.
Massion P, et al: Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridisation: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 2002, 62: 3636-40. 13PubMed
13.
Massion P, et al: Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med. 2004, 170: 1088-94. 10.1164/rccm.200404-487OC. 10CrossRefPubMed
14.
Kim T, et al: Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res. 2005, 11: 8235-42. 10.1158/1078-0432.CCR-05-1157. 23CrossRefPubMed
15.
Tonon G, et al: High-resolution genomic profiles of human lung cancer. Proc Nat Ac Science USA. 2005, 9625-30. 10.1073/pnas.0504126102.
16.
Garnis C, et al: High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer. 2006, 118: 1556-64. 10.1002/ijc.21491.CrossRefPubMed
17.
Graff J, Zimmer S: Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clinical and Experimental Metastasis. 2003, 20: 265-73. 10.1023/A:1022943419011.CrossRefPubMed
18.
Bilanges B, Stokoe D: Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene. 2007, 5973-5990. 10.1038/sj.onc.1210431.
19.
Sahin AA, et al: Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer. 1990, 65: 530-7. 10.1002/1097-0142(19900201)65:3<530::AID-CNCR2820650325>3.0.CO;2-6. 3CrossRefPubMed
20.
Granone P, et al: DNA flow cytometric analysis in patients with operable non-small cell lung carcinoma. Eur J Cardiothorac Surg. 1993, 7: 351-5. 10.1016/1010-7940(93)90065-J. 7CrossRefPubMed
21.
Kasprzyk M, et al: Prognostic value of DNA ploidy: 5-year follow-up of patients with resectable squamous cell carcinoma (SCC) of the lung. Lung Cancer. 2006, 51: 201-6. 10.1016/j.lungcan.2005.10.014. 2CrossRefPubMed
22.
Choi H, et al: Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Human Pathology. 2002, 33: 158-64. 10.1053/hupa.2002.30722. 2CrossRefPubMed
23.
Barbieri C, Barton C, Pietenpol J: Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. The journal of biological chemistry. 2003, 51: 51408-14. 10.1074/jbc.M309943200.CrossRef
24.
Glickman J, et al: Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Human Pathology. 2001, 32: 1157-65. 10.1053/hupa.2001.28951. 11CrossRefPubMed
25.
Di Como C, et al: p63 expression profiles in human normal and tumour tissues. Clin Cancer Res. 2002, 8: 494-501. 2PubMed
26.
Pruneri G, et al: p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest. 2002, 82: 1327-34. 10CrossRefPubMed
27.
Massion P, et al: Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003, 63: 7113-21. 21PubMed
28.
Au N, et al: P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004, 12: 240-47. 3CrossRefPubMed
29.
Van Cutsem E, Nowacki M, Lang I: Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial. J Clin Pathol. 2007, 25: 164s abstr 4000
30.
Thurfjell N, et al: Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol. 2004, 25: 27-35. 1PubMed
31.
Nylander K, et al: Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol. 2002, 198: 417-27. 10.1002/path.1231. 4CrossRefPubMed
32.
De Young MP, et al: Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res. 2006, 66: 9362-8. 10.1158/0008-5472.CAN-06-1619. 19CrossRef
33.
Ebert E, et al: Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol. 1997, 421: 259-65.CrossRefPubMed
34.
Werle B, et al: Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. Oncol Rep. 2006, 16: 647-55. 4PubMed
35.
Scagliotti GV, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008, 26: 3543-51. 10.1200/JCO.2007.15.0375. 21CrossRefPubMed
36.
Takahashi T, et al: p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989, 246: 491-4. 10.1126/science.2554494. 4929CrossRefPubMed
37.
Sekido Y, Fong K, Minna J: Molecular biology of lung cancer. [book auth.] V DeVita, S Hellman and S Rosenberg. Cancer - principles and practice of oncology. s.l. 2001, Lippincott Williams & Wilkins, 1: 917-25.
38.
Pao W, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PloS Med. 2005, 2: c73-10.1371/journal.pmed.0020073. 3CrossRef
39.
Peeters M, et al: Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009, 115: 1544-54. 10.1002/cncr.24088. 7CrossRefPubMed
40.
Bokemeyer C, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009, 27: 663-71. 10.1200/JCO.2008.20.8397. 5CrossRefPubMed
41.
Amado RG, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26: 1626-34. 10.1200/JCO.2007.14.7116. 10CrossRefPubMed
42.
Schmid RS, et al: NCAM stimulates the Ras-MAPK pathway and CREB phosphorylation in neuronal cells. J Neurobiol. 1999, 38: 542-58. 10.1002/(SICI)1097-4695(199903)38:4<542::AID-NEU9>3.0.CO;2-1. 4CrossRefPubMed
43.
Son H, et al: Reciprocal actions of NCAM and tPA via a Ras-dependent MAPK activation in rat hippocampal neurons. Biochem Biophys Res Commun. 2002, 298: 262-8. 10.1016/S0006-291X(02)02453-1. 2CrossRefPubMed
44.
Ramaswamy S, et al: A molecular signature of metastasis in primary solid tumours. Nature Genetics. 2003, 33: 49-54. 10.1038/ng1060.CrossRefPubMed
45.
Weigelt B, et al: Gene expression profiles of primary breast tumours maintained in distant metastases. Proc Nat Acad Sciences USA. 2003, 100: 15901-05. 10.1073/pnas.2634067100. 26CrossRef
46.
Akervall J, et al: The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2003, 9: 1750-5. 5PubMed
47.
Hu Y, et al: Identification and functional characterization of a novel human Misshapen/Nck interacting kinase-related kinase, hMINK-beta. J Biol Chem. 2004, 54387-54397. 10.1074/jbc.M404497200.
48.
Oh J, et al: The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001, 107: 789-800. 10.1016/S0092-8674(01)00597-9.CrossRefPubMed
49.
Chang HC, Cho CY, Hung WC: Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci. 2007, 98: 169-73. 10.1111/j.1349-7006.2006.00367.x. 2CrossRefPubMed
Metadata
Title
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer
Authors
Genni M Newnham
Matthew Conron
SueAnne McLachlan
Alexander Dobrovic
Hongdo Do
Jason Li
Kenneth Opeskin
Natalie Thompson
Gavin M Wright
David M Thomas
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-93

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts

Research article

Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis

Research article

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Research article

Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type

Research article

Exploring the uncertainties of early detection results: model-based interpretation of mayo lung project

Research article

Hakai reduces cell-substratum adhesion and increases epithelial cell invasion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits